Lv4
410 积分 2024-08-09 加入
Real world efficacy and safety of ivosidenib in US veterans with IDH1 mutated cholangiocarcinoma
23天前
已完结
262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study
23天前
已关闭
Final Results from a First-in-Human Phase 1 Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations
1个月前
已完结
An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer
1个月前
已完结
Efficacy and safety of targeted therapy and immune checkpoint inhibitors in patients with advanced or metastatic biliary tract cancer: a meta-analysis of and sequential analysis of trials
1个月前
已完结
Liquid Biopsy in CRC Management: Early Detection, Minimal Residual Disease, and Therapy Optimization—Clinical Evidence and Challenges
2个月前
已完结
Construction of a back propagation neural network model for predicting urosepsis after flexible ureteroscopic lithotripsy based on heparin-binding protein and C-reactive protein levels
3个月前
已完结
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
3个月前
已完结
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
3个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
